A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Ilaprazole (Primary) ; Lansoprazole (Primary)
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors Takeda
- 01 Jan 2008 Status changed from in progress to completed.
- 26 Jul 2007 Status changed from recruiting to in progress.
- 03 Jul 2007 Status change